VKH
OCUL icon

Virtu KCG Holdings’s Ocular Therapeutix OCUL Stock Holding History

Virtu KCG Holdings’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-43,284
Closed -$402K – 3312
2017
Q1 		$402K Buy
+43,284
New +$360K 0.01% 1603
2016
Q4 		– Sell
-13,414
Closed -$92K – 3681
2016
Q3 		$92K Buy
+13,414
New +$81.8K ﹤0.01% 2655

Other funds holding OCUL

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu KCG Holdings's OCUL Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Ocular Therapeutix (OCUL) in Q2 2017, closing a stake of 43,284 shares — an estimated $402K sold.

Virtu KCG Holdings first reported a position in OCUL in Q3 2016 and held it in 2 quarters. The position peaked at $402K in Q1 2017. 72 funds tracked by Wall St. Rank hold OCUL as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Ocular Therapeutix position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 43,284 Ocular Therapeutix shares in Q2 2017, an estimated $402K.
  • Virtu KCG Holdings first reported a position in Ocular Therapeutix in Q3 2016 and held it in 2 quarters.
  • Virtu KCG Holdings's Ocular Therapeutix position peaked at $402K in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.